Treatment of @entity3556 irregularities induced by XXXX only contraceptives.

@entity1 @entity172 @entity3556 @entity353 @entity548 @entity440 @entity2082 @entity3403 @entity344 @entity2692 @entity1871 @entity927 @entity3927 @entity12135 @entity2588
BACKGROUND: Despite their high effectiveness, @entity1871 -only contraceptives are considered less than ideal by the many @entity1 who experience irregular @entity3556 when using them. Current treatments to control these @entity548 problems are not sufficiently effective. OBJECTIVES: We evaluated preventive and therapeutic approaches to normalise @entity548 irregularities associated with the use of @entity1871 -only contraceptives. SEARCH STRATEGY: Literature was identified through database searches, reference lists, organisations and individuals, covering the period until December 2006. SELECTION CRITERIA: Trials with random or alternate allocation, testing interventions for the prevention or treatment of @entity548 irregularities associated with the use of @entity1871 -only contraceptives were eligible. DATA COLLECTION AND ANALYSIS: Results are expressed as relative risks (RR) with 95% confidence interval (CI) for categorical data and as @entity353 ( @entity353 ) with 95% CI for continuous data. When we encountered heterogeneity (visual or statistical) we used the random-effects model (quantitative) or did not produce a summary estimate (qualitative). MAIN RESULTS: Twenty three randomised controlled trials enrolling 2674 @entity1 were included. Seventy per cent were determined to reflect low to moderate risk of bias. @entity172 treatments reduced the number of days of an ongoing @entity548 episode in @entity12135 and Norplant users. However, treatment frequently led to study discontinuation due to @entity344 . Combinations of oral @entity2082 and @entity2692 improved @entity548 patterns in Norplant users, but method discontinuation rates were unchanged. One trial reported successful use of combined oral contraceptives in treating @entity2588 among @entity12135 users. Norplant users, but not Implanon users, administered the anti- @entity1871 mifepristone reported fewer days of @entity548 than those given placebo. Mifepristone used monthly by new Norplant acceptors reduced @entity548 , when compared to placebo.A variety of NSAIDS have been evaluated for their ability to treat @entity548 , with mixed results. Norplant users receiving @entity440 had less unacceptable @entity548 after treatment and were more likely to continue using Norplant than those receiving placebo. @entity927 , @entity3927 combined with an @entity172 and @entity3403 were more effective than placebo in terminating an episode of @entity548 in @entity1 using @entity1871 -only contraceptives, according to three small studies. AUTHORS' CONCLUSIONS: Some @entity1 may benefit from the interventions described, particularly with cessation of current @entity548 . Several regimens offer promise in regulating @entity548 , but findings need to be reproduced in larger trials. The results of this review do not support routine clinical use of any of the regimens included in the trials, particularly for long-term effect.
